Jyong Biotech Ltd.

Jyong Biotech Ltd. is a clinical-stage biopharmaceutical company focused on the development of botanical drug products. The company's primary focus is on advancing its core drug candidate, Botreso, which is undergoing clinical development for the initial treatment of benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS). In addition to Botreso, the company explores other potential indications, such as prostate cancer prevention, as well as candidates designated as PCP and IC. Its future customer base encompasses prospective patients, healthcare providers, and third-party payors within the medical community.

All of the company's key drug candidates remain in preclinical or clinical development phases without commercial sales or marketing approval. The company conducts research and clinical development activities across multiple jurisdictions, including the United States and Taiwan, while considering broader international regulatory pathways. Jyong Biotech Ltd. maintains its principal executive offices and headquarters in New Taipei City, Taiwan, and is incorporated under the laws of the Cayman Islands.

Summary of the business section of Jyong Biotech's latest annual report, written by StockData.